Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial

por Moscetti, Luca, Fabbri, Maria Agnese, Natoli, Clara, Vici, Patrizia, Gamucci, Teresa, Sperduti, Isabella, Iezzi, Laura, Iattoni, Elena, Pizzuti, Laura, Roma, Carmine, Vaccaro, Angela, D’Auria, Giuliana, Mauri, Mariella, Mentuccia, Lucia, Grassadonia, Antonino, Barba, Maddalena, Ruggeri, Enzo Maria
Publicado 2017

Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis o...

por Orlandi, Armando, Iattoni, Elena, Pizzuti, Laura, Fabbri, Agnese, Botticelli, Andrea, Di Dio, Carmela, Palazzo, Antonella, Garufi, Giovanna, Indellicati, Giulia, Alesini, Daniele, Carbognin, Luisa, Paris, Ida, Vaccaro, Angela, Moscetti, Luca, Fabi, Alessandra, Magri, Valentina, Naso, Giuseppe, Cassano, Alessandra, Vici, Patrizia, Giannarelli, Diana, Franceschini, Gianluca, Marchetti, Paolo, Bria, Emilio, Tortora, Giampaolo
Publicado 2020